Phase II trial of arsenic trioxide in relapsed and refractory acute myeloid leukemia, secondary leukemia and/or newly diagnosed patients at least 65 years old

Estey EH, Kantarjian H, Keating MJ. Therapy for Acute Myeloid Leukemia. In: Hoffman R, Benz EJ, Shattil SJ, editors. Hematology basic principles and practice. 3rd ed. New York, NY: Churchill Livingstone; 2000. p. 1025–41. Rees, 1986, Principal results of the Medical Research Council’s 8th acute myeloid leukaemia trial, Lancet, 2, 1236, 10.1016/S0140-6736(86)92674-7 Mayer, 1994, Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B, N. Engl. J. Med., 331, 896, 10.1056/NEJM199410063311402 Buchner, 1999, Double induction strategy for acute myeloid leukemia: the effect of high-dose cytarabine with mitoxantrone instead of standard-dose cytarabine with daunorubicin and 6-thioguanine: a randomized trial by the German AML Cooperative Group, Blood, 93, 4116 Stone, 1995, Granulocyte-macrophage colony-stimulating factor after initial chemotherapy for elderly patients with primary acute myelogenous leukemia. Cancer and Leukemia Group B, N Engl. J. Med., 332, 1671, 10.1056/NEJM199506223322503 Rowe, 1995, A randomized placebo-controlled phase III study of granulocyte-macrophage colony-stimulating factor in adult patients (>55 to 70 years of age) with acute myelogenous leukemia: a study of the Eastern Cooperative Oncology Group (E1490), Blood, 86, 457, 10.1182/blood.V86.2.457.bloodjournal862457 Lowenberg, 1997, Blood, 90, 2952 Godwin, 1998, A double-blind placebo-controlled trial of granulocyte colony-stimulating factor in elderly patients with previously untreated acute myeloid leukemia: a Southwest Oncology Group study (9031), Blood, 91, 3607, 10.1182/blood.V91.10.3607 Lowenberg, 1998, J. Clin. Oncol., 16, 872, 10.1200/JCO.1998.16.3.872 Velu, 1998, Daunorubicin in patients with relapsed and refractory acute non lymphocytic leukemia previously treated with anthracycline, Am J. Haematol., 27, 224, 10.1002/ajh.2830270315 Estey, 2000, Treatment of relapsed and refractory acute myelogenous leukemia, Leukemia, 14, 476, 10.1038/sj.leu.2401568 Lee, 2000, Duration of second complete remission compared with first complete remission in patients with acute myeloid leukemia. Eastern Cooperative Oncology Group, Leukemia, 14, 1345, 10.1038/sj.leu.2401853 Sievers EL, Larson R, Estey E, et al. Comparison of efficacy and safety of gemtuzumab ozogamicin (CMA-676) in patients less than 60 and greater or equal than 60 years of age with AML in first relapse years. Proc Am Soc Clin Oncol 2000;8a. Tallman MS. New developments in targeted therapy for AML. ASCO Annual Educational Book; 2000. p. 110–21. Sievers, 1999, Selective ablation of acute myeloid leukemia using antibody-targeted chemotherapy: a phase I study of an anti-CD33 calicheamicin immunoconjugate, Blood, 93, 3678, 10.1182/blood.V93.11.3678 Baer, 2002, Phase 3 study of the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age and older with acute myeloid leukemia: Cancer and Leukemia Group B Study 9720, Blood, 100, 1224, 10.1182/blood.V100.4.1224.h81602001224_1224_1232 Cutler EG, Bradford EH. Action of iron, cod-liver oil and arsenic on the globular richness of the blood. Am J Med Sci 1878;75. Kwong, 1997, Delicious poison: arsenic trioxide for the treatment of leukemia, Blood, 89, 3487, 10.1182/blood.V89.9.3487 Forkner, 1931, Arsenic as a therapeutic agent in chronic myelogenous leukemia, JAMA, 97, 3, 10.1001/jama.1931.02730010007002 Sears, 1988, History of the treatment of chronic myelocytic leukemia, Am J. Med. Sci., 296, 85, 10.1097/00000441-198808000-00001 Sun, 1992, Ai-Lin 1 treated 32 cases of acute promyelocytic leukemia, Chin J. Integr. Chin West Med., 12, 170 Zhang, 1996, Arsenic trioxide treated 72 cases of acute promyelocytic leukemia, Chin J. Haematol., 17, 58 Shen, 1997, Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients, Blood, 89, 3354, 10.1182/blood.V89.9.3354 Soignet, 1998, Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide, N Engl. J. Med., 339, 1341, 10.1056/NEJM199811053391901 Soignet, 2001, United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia, J. Clin. Oncol., 19, 3852, 10.1200/JCO.2001.19.18.3852 Zhu, 1997, Arsenic-induced PML targeting onto nuclear bodies: implications for the treatment of acute promyelocytic leukemia, Proc. Natl. Acad. Sci. U.S.A., 94, 3978, 10.1073/pnas.94.8.3978 Shao, 1998, Arsenic trioxide as an inducer of apoptosis and loss of PML/RAR alpha protein in acute promyelocytic leukemia cells, J. Natl. Cancer Inst., 90, 124, 10.1093/jnci/90.2.124 Roboz, 2000, Arsenic trioxide induces dose- and time-dependent apoptosis of endothelium and may exert an antileukemic effect via inhibition of angiogenesis, Blood, 96, 1525, 10.1182/blood.V96.4.1525 Miller, 2002, Mechanisms of action of arsenic trioxide, Cancer Res., 62, 3893 Zhu, 1999, Apoptosis and growth inhibition in malignant lymphocytes after treatment with arsenic trioxide at clinically achievable concentrations, J. Natl. Cancer Inst., 91, 772, 10.1093/jnci/91.9.772 Ishitsuka, 2002, Arsenic trioxide induces apoptosis in HTLV-I infected T-cell lines and fresh adult T-Cell leukemia cells through CD95 or tumor necrosis factor alpha receptor independent caspasc activation, Leuk. Lymphoma, 43, 1107, 10.1080/10428190290021461 Lehmann, 2001, Effects of arsenic trioxide (As2O3) on leukemic cells from patients with non-M3 acute myelogenous leukemia: studies of cytotoxicity, Eur. J. Haematol., 66, 357, 10.1034/j.1600-0609.2001.066006357.x Jing, 2001, Combined effect of all-trans retinoic acid and arsenic trioxide in acute promyelocytic leukemia cells in vitro and in vivo, Blood, 97, 264, 10.1182/blood.V97.1.264 Munshi, 2002, Clinical activity of arsenic trioxide for the treatment of multiple myeloma, Leukemia, 16, 1835, 10.1038/sj.leu.2402599 Hussein, 2003, Trials of arsenic trioxide in multiple myeloma, Cancer Control, 10, 370, 10.1177/107327480301000503 Soignet, 2000, Arsenic trioxide (AS2O3): a dose-ranging and clinical pharmacologic study in patients with advanced hematologic cancers, Cancer Res., 41, 543 Dutcher, 2000, Major hematologic response in a patient with myelodysplastic syndrome (MDS) to Arsenic Trioxide (ATO), Blood, 96, 260b List, 2003, Opportunities for Trisenox (arsenic trioxide) in the treatment of myelodysplastic syndromes, Leukemia, 17, 1499, 10.1038/sj.leu.2403021 Bennett, 1991, Proposal for the recognition of minimally differentiated acute myeloid leukaemia (AML-MO), Br. J. Haematol., 78, 325, 10.1111/j.1365-2141.1991.tb04444.x Bennett, 1985, Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French–American–British Cooperative Group, Ann Intern Med., 103, 620, 10.7326/0003-4819-103-4-620 Cryns, 1998, Proteases to die for, Genes Dev., 12, 1551, 10.1101/gad.12.11.1551 Shi, 2002, Mechanisms of caspase activation and inhibition during apoptosis, Mol. Cell., 9, 459, 10.1016/S1097-2765(02)00482-3 Thornberry, 1998, Caspases: enemies within, Science, 281, 1312, 10.1126/science.281.5381.1312 Campos, 1992, Clinical significance of multidrug resistance protein p-glycoprotein expression in acute non-lymphoblastic leukemia cells at diagnosis, Blood, 79, 473, 10.1182/blood.V79.2.473.473 Cheson, 1990, Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia, J. Clin. Oncol., 8, 813, 10.1200/JCO.1990.8.5.813 Simon, 1989, Optimal two-stage designs for phase II clinical trials, Control Clin. Trials, 10, 1, 10.1016/0197-2456(89)90015-9 Soignet, 1999, A phase I study of arsenic trioxide (ATO) in patients with solid tumors, Proc. Am Soc. Clin. Oncol., 18, 878 Huang, 2002, The cytotoxicity of arsenic trioxide to normal hematopoietic progenitors and leukemic cells is dependent on their cell-cycle status, Leuk. Lymphoma, 43, 2191, 10.1080/1042819021000032980 Pallis, 2002, p-Glycoprotein in acute myeloid leukaemia: therapeutic implications of its association with both a multidrug-resistant and an apoptosis-resistant phenotype, Leuk. Lymphoma, 43, 1221, 10.1080/10428190290026277 Arceci, 1993, Clinical significance of p-glycoprotein in multidrug resistance malignancies, Blood, 81, 2215, 10.1182/blood.V81.9.2215.2215 den Boer, 1998, Relationship between major vault protein/lung resistance protein, multidrug resistance-associated protein, p-glycoprotein expression, and drug resistance in childhood leukemia, Blood, 91, 2092, 10.1182/blood.V91.6.2092.2092_2092_2098 Liu, 2003, Arsenic trioxide-induced apoptosis in myeloma cells: p53-dependent G1 or G2/M cell cycle arrest, activation of caspase 8 or caspase 9 and synergy with APO2/TRAIL, Blood, 101, 4078, 10.1182/blood-2002-10-3231 Akao, 2000, Arsenic-induced apoptosis in malignant cells in vitro, Leuk Lymphoma, 37, 53, 10.3109/10428190009057628 Camacho, 2000, Leukocytosis and the retinoic acid syndrome in patients with acute promyelocytic leukemia treated with arsenic trioxide, J. Clin. Oncol., 18, 2620, 10.1200/JCO.2000.18.13.2620 Jing, 2002, Effect of arsenic trioxide on different cell lines derived from chronic myeloid leukemia, Zhongguo Shi Yan Xue Ye Xue Za Zhi., 10, 413 Mahieux, 2001, Arsenic trioxide induces apoptosis in human T-cell leukemia virus type 1- and type 2-infected cells by a caspase 3-dependent mechanism involving Bcl-2 cleavage, Blood, 98, 3762, 10.1182/blood.V98.13.3762 Kitamura, 2000, Involvement of CD95-independent caspase 8 activation in arsenic trioxide-induced apoptosis, Leukemia, 14, 1743, 10.1038/sj.leu.2401900 Ashkenazi, 1998, Death receptors: signaling and modulation, Science, 281, 1305, 10.1126/science.281.5381.1305 Lacour, 2001, Anticancer agents sensitize tumor cells to tumor necrosis factor-related apoptosis-inducing ligand-mediated caspase-8 activation and apoptosis, Cancer Res., 61, 1645 Mitsiades, 2002, Intracellular regulation of tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human multiple myeloma cells, Blood, 99, 2162, 10.1182/blood.V99.6.2162 Adams, 1998, The Bcl-2 protein family: arbiters of cell survival, Science, 281, 1322, 10.1126/science.281.5381.1322 Fenaux, 1999, A randomized comparison of all trans retinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia. The European APL Group, Blood, 94, 1192, 10.1182/blood.V94.4.1192 Munshi, 2002, Clinical activity of arsenic trioxide for the treatment of multiple myeloma, Leukemia, 16, 1835, 10.1038/sj.leu.2402599 Niu, 1999, Studies on treatment of acute promyelocytic leukemia with arsenic trioxide: remission induction, follow-up, and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients, Blood, 94, 3315, 10.1182/blood.V94.10.3315.422k16_3315_3324 Soignet, 1999, U.S. Multicenter trial of arsenic trioxide (ATO) in acute promyelocytic leukemia (APL), Blood, 94, 698a Chen, 1996, In vitro studies on cellular and molecular mechanisms of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia: As2O3 induces NB4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PML-RAR alpha/PML proteins, Blood, 88, 1052, 10.1182/blood.V88.3.1052.1052 Bachleitner-Hofmann, 2001, Arsenic trioxide and ascorbic acid: synergy with potential implications for the treatment of acute myeloid leukaemia?, Br. J. Haematol., 112, 783, 10.1046/j.1365-2141.2001.02608.x Bahlis, 2002, Feasibility and correlates of arsenic trioxide combined with ascorbic acid-mediated depletion of intracellular glutathione for the treatment of relapsed/refractory multiple myeloma, Clin. Cancer Res., 8, 3658 Huang, 2000, Potentiation of arsenic trioxide-induced apoptosis by retinoic acid in retinoic acid sensitive and resistant HL-60 myeloid leukemia cells, Chin Med. J. (Engl.), 113, 498 Sakurai, 2002, A major human arsenic metabolite, dimethylarsinic acid, requires reduced glutathione to induce apoptosis, Chem Res. Toxicol., 15, 629, 10.1021/tx0101604 Shen, 1999, Glutathione synthesis inhibitor enhances arsenic trioxide-induced apoptosis, Zhonghua Zhong Liu Za Zhi., 21, 259 Grad, 2001, Ascorbic acid enhances arsenic trioxide-induced cytotoxicity in multiple myeloma cells, Blood, 98, 805, 10.1182/blood.V98.3.805 Gartenhaus, 2002, Arsenic trioxide cytotoxicity in steroid and chemotherapy-resistant myeloma cell lines: enhancement of apoptosis by manipulation of cellular redox state, Clin. Cancer Res., 8, 566 Yuksel, 2002, Arsenic trioxide and methylprednisolone use different signal transduction pathways in leukemic differentiation, Leuk Res., 26, 391, 10.1016/S0145-2126(01)00147-3 Estrov, 1999, Phenylarsine oxide blocks interleukin-1beta-induced activation of the nuclear transcription factor NF-kappaB, inhibits proliferation, and induces apoptosis of acute myelogenous leukemia cells, Blood, 94, 2844, 10.1182/blood.V94.8.2844.420k43_2844_2853 Oetken, 1992, Phenylarsine oxide augments tyrosine phosphorylation in hematopoietic cells, Eur. J. Haematol., 49, 208, 10.1111/j.1600-0609.1992.tb00048.x Konig, 1997, Comparative activity of melarsoprol and arsenic trioxide in chronic B-cell leukemia lines, Blood, 90, 562, 10.1182/blood.V90.2.562 Soignet, 1999, Clinical study of an organic arsenical, melarsoprol, in patients with advanced leukemia, Cancer Chemother Pharmacol., 44, 417, 10.1007/s002800050998